Last reviewed · How we verify

NCT05055440

Evaluation of Peripheral Muscle With Ultrassonografic of Critical Patients With Covid-19

Completed Last updated 2 August 2022
What this trial tests

trial in COVID-19 Respiratory Infection in 30 participants. Completed in 30 June 2022.

Timeline
20 December 2021
Primary endpoint
20 May 2022
30 June 2022

Quick facts

Lead sponsorUniversity of Pernambuco
StatusCompleted
Study typeOBSERVATIONAL
Enrollment30
Start date20 December 2021
Primary completion20 May 2022
Estimated completion30 June 2022
Sites1 location across Brazil

Conditions studied

Sponsor

University of Pernambuco

Who can join

Adults 18 to 80, any sex, with COVID-19 Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Currently, the tools available for assessing peripheral muscle dysfunction in the intensive care setting require patient collaboration. Several studies have shown that peripheral muscle ultrasound is capable of reliably detecting morphological changes in critically ill patients, in addition to contributing to the identification of patients at higher risk of prolonged complications, especially when performed daily. In this sense, a valid, non-volitional alternative capable of determining muscle mass is through ultrasound assessment. However, current studies are characterized by a lack of standardization in their protocols, which include proper positioning of limbs, transducer, clear reference points and techniques for better visualization of the assessed muscle, in addition to significant methodological defects and inadequate sample sizes. We believe that, together with a tool capable of determining muscle mass and being a safe and non-invasive method, we can contribute to a more complete assessment of these patients, exploring outcomes such as survival, length of stay in the ICU, extubation success and functional capacity. In addition to having the potential to serve as a biomarker of muscle strength during rehabilitation, given little knowledge about the long-term physical consequences of COVID-19, thus promoting a more complete assessment, exploring morphological characteristics of the peripheral muscles resulting from the hospitalization process. and assisting the physiotherapist in clinical decision making in rehabilitation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for COVID-19 Respiratory Infection

Currently open trials in the same condition.

Other University of Pernambuco trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05055440.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing